Articles related to OBESITY/WEIGHT MANAGEMENT

Because this GLP-1 agonist is known to reduce food intake, physicians have been prescribing tirzepatide off-label for weight loss for years. But unlike other drugs in its class, tirzepatide targets GLP-1 and GIP receptors.

The founding editor of Comprehensive Clinical Nephrology teases out for us our physiologic response to salt, sugar, fat, and water that creates a recipe for obesity – a recipe being used daily by many Americans with obvious results. His recommendation? “Drinking more water and reducing salt intake offer cheap, easy and healthy strategies that may prevent or treat obesity.” Click to see the evidence behind the conclusion.

A follow-up to the discussion we recently presented, this article asks doctors to look beyond the physical health of the patient to recognize and potentially treat muscle dysmorphia, the notion in which an individual is preoccupied with the idea that his or her body build is too small or insufficiently muscular.

Although many studies have claimed that moderate alcohol consumption and drinks such as red wine can be healthy for the human heart, a new study presented at the European Society of Cardiology 2022 meeting takes a contrarian viewpoint and draws a link between alcohol consumption and heart failure in people with hypertension, diabetes, or obesity.

Lilly Pharmaceutical’s Mounjaro (tirzepatide) is a once-weekly injection that promotes weight loss by mimicking the effects of incretins. This combination of a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) yields weigh loss results comparable to surgical options.

Among adults aged 35 years or older with a body mass index (BMI) of 25 kg/m2, the prevalence of diabetes in Asian, Black, and Hispanic Americans was significantly higher than that in White Americans. Using screening thresholds specific to race and ethnicity has the potential to reduce disparities in diabetes diagnosis.